UPDATED RESULTS OF PHASE 3 STELLAR TRIAL: EFLORNITHINE IMPROVES OVERALL SURVIVAL AND BLINDED INDEPENDENT CENTRAL REVIEW DETERMINED PROGRESSION FREE SURVIVAL IN PATIENTS WITH RECURRENT WHO 2021 GRADE 3 IDH-MUTANT ASTROCYTOMA